Intravenous arsenic trioxide (ATO) has been adopted as the first-line treatment for acute promyelocytic leukemia (APL). Another arsenic compound named the Realgar-Indigo naturalis formula (RIF), an oral traditional Chinese medicine containing As 4 S 4 , has been shown to be highly effective in treating adult APL. In the treatment of pediatric APL, the safety and efficacy of RIF remains to be confirmed. This randomized, multicenter, and noninferiority trial was conducted to determine whether intravenous ATO can be substituted by oral RIF in the treatment of pediatric APL. From September 2011 to January 2017, among 92 patients who were 16 years old or younger with newly diagnosed PML-RARa positive APL, 82 met eligible criteria and were randomly assigned to ATO (n = 42) or RIF (n = 40) group. The remaining 10 patients did not fulfilled eligible criteria because five did not accept randomization, four died and one had hemiplegia prior to arsenic randomization due to intracranial hemorrhage or cerebral thrombosis. Induction and consolidation treatment contained ATO or RIF, all-trans-retinoic acid and low intensity chemotherapy. End points included event-free survival (EFS), adverse events and hospital days.
can be administered outside the hospital, reducing the number of hospital days compared to intravenous ATO. 15, 16 There is limited data on the role of RIF in the treatment of pediatric patients. Some small retrospectively studies including ours suggested that RIF is also safe and effective in children with APL, 17, 18 with less cardiac toxicity compared to ATO. 18 These, however, remain to be confirmed. South China Children Leukemia Group (SCCLG) conducted a randomized study to compare the efficacy, safety and the number of hospital days between RIF-and ATO-based therapies for treating pediatric APL. The ultimate aim of the study is to determine whether intravenous ATO can be substituted by oral RIF in the treatment of pediatric APL.
| PATIENTS AND METHODS

| Study design
The SCCLG-APL study was a prospective, randomized, multicenter, open-label, noninferiority trial. It was designed to show that the combination of RIF plus ATRA and CHT is not inferior to ATO plus ATRA and CHT in terms of EFS at 5 years. The study was started in September 2011 and included nine participating hospitals, and was joined by another five hospitals thereafter until the deadline in September 2016 for enrolling new hospital in the study. The trial was retrospectively registered in February 2014 at www.clinicaltrials.gov as NCT02200978.
Eligible patients were 16 years old or younger with newly diagnosed APL with confirmation of PML-RARa by RT-PCR assay AE fluorescence in situ hybridization (FISH), and randomly assigned by computer-generated codes to ATO or RIF group. The excluded patients were those who had one of the following events occurring before genetic diagnosis and randomization: death from any cause, or coma, convulsion, paralysis due to intracranial hemorrhage, cerebral thrombosis or central nervous system leukemia; or who had prolonged QT syndrome because of the risk of QT interval prolongation during arsenic therapy; or who did not accept randomization. The study received institutional review board approval.
Patients' families and/or patients provided informed consent in accordance with the Declaration of Helsinki.
The primary end point was the rate of EFS at 5 years. Secondary end points were safety and the number of accumulated hospital days during induction and consolidation therapy.
| Treatment protocol
The details of treatment protocols are shown in Figure RT-PCR for determining PML-RARa expression was performed for genetic diagnosis of APL and monitoring of minimal residual disease after treatment ( Figure 1 ).
| Supportive therapy
At the initiation of and during induction therapy, when patients' WBC count was over 10 × 10 9 /L, hydroxyurea (100 mg/kg/day) was administered until WBC <10 × 10 9 /L. Dexamethasone (0.3 mg/kg/ day) was given if differentiation syndrome or ATRA-associated pseudotumor cerebri was suspected. The use of heparin or low-molecular weight heparins for management of coagulopathy was not mandatory but encouraged because ATRA might increase thrombosis risk. 22, 23 Heparin was given at a low dose of 0.5-1 mg/kg intravenously for 24 hours daily if indicated until the coagulopathy resolved.
Transfusions of platelet, and fresh-frozen plasma, cryoprecipitate and/or human fibrinogen, were given for the aims of maintaining platelet counts greater than 30 × 10 9 /L, and fibrinogen greater than 1.5 g/L, respectively.
| Statistical analysis
The Kaplan-Meier method was used to estimate overall survival were required to draw a noninferiority conclusion. Noninferiority was to be concluded if the lower limit of the 95% CI for the rate difference of EFS was greater than −10% noninferiority margin. Analysis was per protocol. Interim analysis of the results was to be performed after enrolling 50% of evaluable patients treated for at least 1 year.
3 | RESULTS
| Enrollment and patient characteristics
The enrollment period of this interim study was from September 2011 to January 2017. The present analysis was performed in Table 1 . There were no significant differences in the baseline characteristics between the two # Bone marrow examination is considered for evaluating the achievement of HCR or HCRp when no leukemic cell was found in peripheral blood.
□ Patients were randomly assigned to ATO or RIF group when the diagnosis was genetically confirmed (5-6 days later), and then ATO or RIF was started and ATRA was continued until HCR/HCRp or for a maximum of 42 days.
△
The doses of 6MP and MTX were adjusted to maintain the WBC of patients between 2 and 3.5 × 10 9 /L groups except for a lower median age in the ATO group than that in the RIF group (7.8 vs 9.9 years, P = .028). For the total of 82 eligible patients (including the one who was withdrawn from the study in consolidation phase), the median followup was 3.0 (range, 0.5-6.4) years. The estimated 5-year OS and EFS rates were 100% in both the two groups ( Figure S1 ).
| Response data
| Toxicity data
Treatment-related adverse effects are listed in Table 2 . increase by more than 30% as compared with that at diagnosis, respectively. The leukocytosis was successfully managed in all patients as per protocol recommendation, and the incidence of differentiation syndrome, including moderate and severe forms, 24 was low in our cohort. The incidence rates of infection, fever of unknown origin and headache were lower in the RIF group than in the ATO group. In addition, coagulopathy events newly occurring during induction phase
were not commonly seen in the enrolled patients ( Table 2 , Supporting
Information Table S2 ).
| Hospital days
The mean accumulated days required for inpatient management during induction and consolidation therapy was 67.8 AE 22.4 and 43.9 AE 19.3 for non-high-risk patients in the ATO and RIF groups (P = .000), and 68.1 AE 19.6 and 48.1 AE 18.6 for high-risk patients in the ATO and RIF groups (P = .029), respectively (Supporting Information Table S2 ). As expected, peripherally inserted central catheter line was placed less frequently in patients in the RIF group than in the ATO group (22.5% vs 92.9% (P = .000).
| DISCUSSION
We here present our findings from a randomized clinical trial comparing the efficacy and safety of oral RIF and intravenous ATO in children with APL in all risk groups. After a median follow-up of 3 years, this interim analysis shows that the estimated rate of EFS and OS at 5 years is not deferent between the pediatric patients in the two groups, when RIF/ATO is used in combination with ATRA and lowintensity chemotherapy.
The rates of treatment-related adverse events were similar in the two groups, except for the incidences of infection and fever of unknown origin which were significantly lower in the RIF group. RIF can be taken orally in an outpatient setting when the disease was stable, which decrease the risk of cross infection in hospital and iatrogenic infection due to PICC line placement, all together resulting in shorter hospital stays.
There is no difficulty encountered with children taking RIF. For young children to make RIF easier to be taken, the pill is triturated with water, and with addition of sugar if necessary because RIF tastes bland with a little bit of bitter if triturated.
To our knowledge, only one study group (Chinese APL Cooperative Group) has reported prospective studies investigating the role of RIF in adult APL till now. 5, [14] [15] [16] In one of the studies, 20 adults with non-high-risk APL were treated with a chemotherapy-free protocol with oral RIF and ATRA and remained molecular remission after 14-month median follow-up, and half of the patients completed induction therapy in an outpatient setting. 15 This "largely home-based treatment protocol" may be a promising new treatment approach for non-high-risk APL, although a long-term observation in a larger number of patients is still needed. In a randomized clinical trial conducted by the same study group, 14 adults with all risk APL (except those with WBC > 50 × 10 9 /L) received ATRA with ATO or RIF for induction and maintenance therapies, between which patients received three (93.7% vs 89.4%, P = .37) were similar between the two groups. 5 Although APL in children shares many features with APL in adults, there are important distinctions between these age groups, and the efficacy and safety data from clinical trial restricted to adult patients needs to be proven in children. 25 There have been two reports including ours, which are small retrospective studies, 17, 18 demonstrating the treatment role of RIF in children with APL and Abbreviations: ATO, arsenic trioxide; ATRA, all-trans-retinoic acid; FUO, fever of unknown origin. a One non-high-risk patient in the RIF group was withdrawn from the study in consolidation phase and lost to follow-up.
The issue of how best to treat patients with APL remains to be and RIF on cardiac function and childhood growth and development.
Moreover, there were five PML-RARa positive patents in our cohort excluded from our study according to the eligibility criteria, because they had severe intracranial hemorrhage or cerebral thrombosis before randomization. Of the five patients, four with intracranial hemorrhage died and one with cerebral thrombosis remained in continuous CR with left hemiplegia for 3 years on our ATO protocol. The risk of hemorrhagic death during the induction period remains at about 5% in the clinical trial setting, 37 and the mortality rate before diagnosis is still unknown. If the survival rate including those patients who die early, it will be lower.
In conclusion, this interim analysis shows that oral RIF is effective and safe and might not be inferior to intravenous ATO as first-line treatment of pediatric APL, at least when combined with ATRA and low intensity chemotherapy. Final trial analysis will reveal mature outcome data. When combined with previous studies on adult APL, this data indicates that substitution of RIF for ATO has the advantage of significantly reducing hospital days and may be a new standard future strategy for treatment of APL patients in all age groups including children.
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